Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 41–50, page 5 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 TrialResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-diad-6month-amyloid-pet-results-from-the-diantu001-trial-41447716

   … anti‐amyloid‐beta antibody lecanemab. Herein, we provide the first results of lecanemab (open‐label) on amyloid PET in a symptomatic DIAD population (the asymptomatic cohort will be evaluated later). Methods The DIAN‐TU‐001 Tau …

2. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-a-second-in-class-therapy-for-the-management-of-early-38779110

   … traditional approval of lecanemab for the treatment of Alzheimer's disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets Aβ soluble …

3. Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and LecanemabResearch summary

   Research summaries · alzhub.org/study/monoclonal-antibody-treatments-for-alzheimer-s-disease-aducanumab-and-39726673

   … gantenerumab, solanezumab, and lecanemab. These treatment approaches are grounded in the hypothesis that a systemic failure in clearing Aβ contributes to the initiation and progression of AD. Recently, aducanumab and lecanemab …

4. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic reviewResearch summary

   Research summaries · alzhub.org/study/novel-anti-amyloid-beta-a-monoclonal-antibody-lecanemab-for-alzheimer-37902139

   The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and is administered intravenously. Based on the clinical trials included …

5. Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain WestResearch summary

   Research summaries · alzhub.org/study/real-world-experience-with-lecanemab-therapy-for-alzheimers-disease-b62fc105

   INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of Alzheimer’s disease. Here, we report on the clinical history and outcomes of the first 70 patients at the …

6. The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microgliaResearch summary

   Research summaries · alzhub.org/study/the-alzheimer-s-therapeutic-lecanemab-attenuates-a-pathology-by-41286448

   … we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector functions. Using a human microglia xenograft mouse model, we show that Lecanemab significantly …

7. The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in SwedenResearch summary

   Research summaries · alzhub.org/study/the-cost-effective-price-of-lecanemab-for-patients-with-early-40730714

   … cost-effective price for lecanemab for treating early Alzheimer's disease in Sweden from the perspective of formal care payers. Methods We developed a Markov model with states defined by disease severity and care setting. The …

8. Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/updated-safety-results-from-phase-3-lecanemab-study-in-early-38730496

   … at least one dose of lecanemab (Core + OLE) were included. This report gives updated safety results from a phase 3 lecanemab study in early Alzheimer's disease, covering 1795 participants in the core study and 1612 who received …

9. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemabResearch summary

   Research summaries · alzhub.org/study/a-real-world-disproportionality-analysis-of-fda-adverse-event-40242445

   … (AEs) associated with lecanemab have been limited. Results A total of 811 AEs reports related to lecanemab used in AD patients and 506 AEs in Non-AD patients were included. Among these, ARIA-E, ARIA-H, brain oedema and status …

10. Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer DiseaseResearch summary

    Research summaries · alzhub.org/study/changes-of-a-cerebral-cavernous-malformation-associated-with-40584633

    … treatment with intravenous lecanemab. Baseline MRI revealed 3 lobar microhemorrhages and an asymptomatic left orbitofrontal cavernous malformation. This cavernous malformation exhibited gross radiologic stability at surveillance …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-05. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.